Unicycive Therapeutics, Inc. (UNCY)
3.59
-0.11
(-2.97%)
USD |
NASDAQ |
Oct 15, 16:00
3.65
+0.06
(+1.67%)
After-Hours: 20:00
Unicycive Therapeutics Enterprise Value : 39.31M for Oct. 15, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 15, 2026 | 39.31M |
| October 14, 2026 | 42.38M |
| October 13, 2026 | 43.21M |
| October 12, 2026 | 52.13M |
| October 09, 2026 | 53.80M |
| October 08, 2026 | 52.68M |
| October 07, 2026 | 55.75M |
| October 06, 2026 | 57.14M |
| October 05, 2026 | 56.03M |
| October 02, 2026 | 56.86M |
| October 01, 2026 | 66.05M |
| September 30, 2026 | 70.09M |
| September 29, 2026 | 66.05M |
| September 28, 2026 | 68.56M |
| September 25, 2026 | 70.09M |
| September 24, 2026 | 73.30M |
| September 23, 2026 | 73.30M |
| September 22, 2026 | 77.48M |
| September 21, 2026 | 72.18M |
| September 18, 2026 | 73.02M |
| September 17, 2026 | 72.18M |
| September 16, 2026 | 72.46M |
| September 15, 2026 | 70.51M |
| September 14, 2026 | 82.77M |
| September 11, 2026 | 86.67M |
| Date | Value |
|---|---|
| September 10, 2026 | 87.22M |
| September 09, 2026 | 81.93M |
| September 08, 2026 | 79.43M |
| September 04, 2026 | 83.05M |
| September 03, 2026 | 86.95M |
| September 02, 2026 | 83.88M |
| September 01, 2026 | 79.98M |
| August 31, 2026 | 84.16M |
| August 28, 2026 | 85.97M |
| August 27, 2026 | 92.52M |
| August 26, 2026 | 90.57M |
| August 25, 2026 | 91.68M |
| August 24, 2026 | 88.06M |
| August 21, 2026 | 96.14M |
| August 20, 2026 | 91.12M |
| August 19, 2026 | 94.75M |
| August 18, 2026 | 96.14M |
| August 17, 2026 | 94.47M |
| August 14, 2026 | 92.80M |
| August 13, 2026 | 89.73M |
| August 12, 2026 | 89.45M |
| August 11, 2026 | 78.59M |
| August 10, 2026 | 79.15M |
| August 07, 2026 | 80.54M |
| August 06, 2026 | 79.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.510B |
| Alnylam Pharmaceuticals, Inc. | 30.98B |
| Anika Therapeutics, Inc. | 263.73M |
| Savara, Inc. | 830.97M |
| Vericel Corp. | 2.031B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.722M |
| Total Expenses (Quarterly) | 1.722M |
| EPS Diluted (Quarterly) | -0.064 |
| Earnings Yield | -44.47% |
| Normalized Earnings Yield | -40.65 |